Sean Harper

Type: Person
Name: Sean Harper
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

Razor Ruddick to help Prospect appeal

FOOTBALL star and TV personality Neil ‘Razor’ Ruddock will grace fans with his presence at an exclusive dinner in aid of the Adver’s 160 Appeal for Prospect Hospice.The retired sportsman, who played for Tottenham Hotspur, Liverpool, West Ham and Swindon ... [Publicerad Swindon Advertiser - Apr 19 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Amgen’s Melanoma Drug Study Misses Secondary Endpoint

By Estel Grace MasangkayAmgen reported that the Phase III trial evaluating its melanoma drug met its primary endpoint with top-line results but missed its secondary endpoint of overall survival.The global, open-label, randomized, Phase III trial assessed ... [Publicerad Bioresearch Online - Apr 08 2014]
First reported Apr 06 2014 - Updated Apr 06 2014 - 1 reports

Disappointing results with Amgen’s talimogene laherparepvec in metastatic melanoma

Leading independent biotech firm Amgen (Nasdaq: AMGN) has released mixed top-line results from the primary overall survival (OS) analysis of a Phase III trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment ... [Publicerad Pharma Letter - Apr 06 2014]
First reported Apr 04 2014 - Updated Apr 05 2014 - 4 reports

Amgen Melanoma Drug Trial Misses OS Endpoint

Amgen announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected Stage IIIB, IIIC or IV melanoma compared ... [Publicerad Drug Discovery and Development - Apr 04 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Amgen reveals further positive cholesterol drug data

:58 in Pharmaceutical Company Product News Amgen has presented new data from a pair of phase III trials that further underline the clinical benefits of its promising cholesterol-lowering medication evolocumab. Positive results from the two separate studies, ... [Publicerad Zenopa - Apr 03 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Amgen reports positive trial data for cholesterol-lowering drug

:58 in Pharmaceutical Company Product News Amgen has announced detailed findings from three phase III clinical trials that demonstrate the strong performance of the investigational cholesterol-lowering medicine evolocumab. New data from the studies that ... [Publicerad Zenopa - Apr 02 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

More strong Ph III data for Amgen's PCSK9 Inhibitor

Biotechnology giant Amgen has presented a run of strong clinical data for evolocumab at the American College of Cardiology meeting, backing its bid to get the first PCSK9 inhibitor to market for the reduction of cholesterol.Among the results were those ... [Publicerad Pharma Times - Mar 31 2014]
First reported Mar 18 2014 - Updated Mar 19 2014 - 2 reports

Amgen's cholesterol-lowering antibody shines in rare disease trial

Amgen's cholesterol-lowering antibody evolocumab has scored another direct hit in a phase 3 clinical trial, this time showing its efficacy in patients with a serious genetic disorder of lipid metabolism.The Tesla study enrolled 49 patients with homozygous ... [Publicerad PMLive - Mar 19 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 2 reports

Amgen vaccine produces strong melanoma trial performance

:48 in Pharmaceutical Company Product News Amgen has presented further results from late-stage trials of its T-Vec cancer vaccine, which has again performed strongly. A retrospective analysis of patients with metastatic melanoma who had been injected ... [Publicerad Zenopa - Mar 18 2014]
First reported Mar 17 2014 - Updated Mar 18 2014 - 3 reports

Amgen's PCSK9 inhibitor shines again in Ph III

There was more good news from Amgen this week after another batch of positive late-stage data for its novel cholesterol buster put it ahead in the race to get the first PCSK9 inhibitor to market.The latest in a stream of successful Phase III trials of ... [Publicerad Pharma Times - Mar 18 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 3 reports

Amgen's Cancer Drug Shrinks Melanoma Tumors

Amgen announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts of the ... [Publicerad Drug Discovery and Development - Mar 17 2014]
First reported Mar 16 2014 - Updated Mar 16 2014 - 2 reports

Amgen vaccine T-Vec shines again in melanoma trial

Amgen's closely-watched cancer vaccine T-Vec has again impressed in late-stage trials for melanoma.The biotech major has presented results from a retrospective analysis of patients with metastatic melanoma injected with T-Vec, also known as talimogene ... [Publicerad Pharma Times - Mar 16 2014]

More Content

All (32) | News (30) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Razor Ruddick to help Prospect appeal [Publicerad Swindon Advertiser - Apr 19 2014]
Obituaries February 12, 2014 [Publicerad Barton Chronicle - Apr 11 2014]
Amgen’s Melanoma Drug Study Misses Secondary En... [Publicerad Bioresearch Online - Apr 08 2014]
Disappointing results with Amgen’s talimogene l... [Publicerad Pharma Letter - Apr 06 2014]
Amgen's closely watched melanoma prospect misse... [Publicerad FierceVaccines - Apr 04 2014]
Amgen Melanoma Drug Trial Misses OS Endpoint [Publicerad Drug Discovery and Development - Apr 04 2014]
Amgen's talimogene laherparepvec misses seconda... [Publicerad FirstWord Pharma - Apr 04 2014]
Amgen's viral cancer vaccine misses its surviva... [Publicerad FierceBiotech - Apr 04 2014]
Amgen Updates On Talimogene Laherparepvec Phase... [Publicerad RTTNews.com - Apr 04 2014]
Amgen reveals further positive cholesterol drug... [Publicerad Zenopa - Apr 03 2014]
Amgen reports positive trial data for cholester... [Publicerad Zenopa - Apr 02 2014]
ACC 2014: Amgen’s evolocumab reduces cholestero... [Publicerad Pharma Letter - Mar 31 2014]
More strong Ph III data for Amgen's PCSK9 Inhib... [Publicerad Pharma Times - Mar 31 2014]
Eyeing rival mAb mob, Novartis touts PhIII secu... [Publicerad FierceBiotech - Mar 24 2014]
Amgen's cholesterol-lowering antibody shines in... [Publicerad PMLive - Mar 19 2014]
Success for Amgen’s 'bad' cholesterol injection [Publicerad Pharmafocus - Mar 18 2014]
Avoca Notebook – March 17 [Publicerad Wicklownews.net - Mar 18 2014]
Amgen vaccine produces strong melanoma trial pe... [Publicerad Zenopa - Mar 18 2014]
Cancer Vaccine From Amgen Gives Hope for Melano... [Publicerad The Guardian Express - Mar 18 2014]
Amgen's PCSK9 inhibitor shines again in Ph III [Publicerad Pharma Times - Mar 18 2014]
Amgen's Cancer Drug Shrinks Melanoma Tumors [Publicerad Drug Discovery and Development - Mar 17 2014]
More positive Ph III data for Amgen’s evolocumab [Publicerad Pharma Letter - Mar 17 2014]
Amgen reports positive results of Phase III mel... [Publicerad Pharmaceutical Business Review - Mar 17 2014]
Amgen's experimental dyslipidaemia drug evolocu... [Publicerad FirstWord Pharma - Mar 17 2014]
Amgen melanoma vaccine shrinks tumours [Publicerad Pharmafocus - Mar 17 2014]
Amgen vaccine T-Vec shines again in melanoma trial [Publicerad Pharma Times - Mar 16 2014]
Retrospective analysis shows tumor shrinkage wi... [Publicerad Pharma Letter - Mar 16 2014]
Amgen’s Cholesterol-Fighting Drug Succeeds Yet ... [Publicerad Wall St. Cheat Sheet - Jan 31 2014]
MGH-Broad-Amgen collaboration to develop new in... [Publicerad Pharmaceutical Technology - Jan 17 2014]
Amgen releases interim results of Phase III tri... [Publicerad Pharmaceutical Business Review - Nov 20 2013]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Amgen’s Cholesterol-Fighting Drug Succeeds Yet ... [Publicerad Wall St. Cheat Sheet - Jan 31 2014]
Amgen Inc.’s ( NASDAQ:AMGN ) experimental anti-cholesterol drug, evolocumab, was successful in its fifth late-stage trial. The treatment targets a protein called PCSK9 that’s typically associated with high levels of “bad” cholesterol (or, LDL),  ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.